drugset / Trial / NCT06196762
Phase I of XKH002 Injection in Patients
NaSequentialOpen-labelTreatment
Summary
This is a Phase 1, first-in-human (FIH), open-label, multicenter, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of XKH002 in patients with advanced or metastatic solid tumors.
Timeline
- Start
- 2023-11-27
- Primary completion
- 2025-12-01
- Completion
- 2026-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XKH002 | Unknown | 0.3 mg/kg | — |
| Subject | XKH002 | Unknown | 1 mg/kg | — |
| Subject | XKH002 | Unknown | 3 mg/kg | — |
| Subject | XKH002 | Unknown | 10 mg/kg | — |
| Subject | XKH002 | Unknown | 20 mg/kg | — |
Indications
No indication recorded.